omalizumab

pharmaceutical drug

Details

Instance of: type of chemical entity
Subclass of: chemical compound
Has parts: carbon
active ingredient in: Xolair
defined daily dose: 16.0
has characteristic: biopharmaceutical
has use: medication
legal status (medicine): boxed warning
medical condition treated: angioedema, status asthmaticus, allergic bronchopulmonary aspergillosis, respiratory disease, urticaria
subject has role: anti-allergic agents, antiasthmatic, monoclonal antibody
World Health Organisation international non-proprietary name: omalizumab

Nothing in the MetaHistoryBook collection references this item yet.